Document Detail

Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury.
MedLine Citation:
PMID:  10453939     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIMS: Hydrophobic bile acids, such as deoxycholic acid produce cholestatic liver injury. Ursodeoxycholic acid has been shown to be useful in the treatment of cholestatic liver disease. METHODS: In this study, we investigated the effects of deoxycholic acid or ursodeoxycholic acid (1% of diet, for 14 days) and their combination (1% each) on expression of hepatic cytochrome P450 isozymes, their related enzyme activities and mRNA level in rats. RESULTS: Adding 1% deoxycholic acid to chow caused a marked increase in serum total bilirubin (47-fold) and total bile acid (8-fold) concentrations and in alkaline phosphatase (2.5-fold, p<0.01) and alanine aminotransferase activities (23.5-fold, p<0.01). Adding the same dose of ursodeoxycholic acid along with the deoxycholic acid mitigated both the rise in serum total bilirubin and bile acid concentrations and that in alkaline phosphatase and alanine aminotransferase activities, although the use of ursodeoxycholic acid alone did not affect any of the above. Feeding 1% deoxycholic acid caused a decrease (48% of control) in total cytochrome P450 content in hepatic microsomes. Addition of 1% ursodeoxycholic acid along with the 1% deoxycholic acid completely prevented the decrease in total cytochrome P450 content. Feeding ursodeoxycholic acid alone did not affect the total cytochrome P450 content. The expression of cytochrome P450 2B1, 2E1, 3A2, 2C6, 2C11 and 4A1 proteins in hepatic microsomes was decreased by deoxycholic acid (44, 51, 23, 59, 30 and 74% of control, respectively). Likewise, the activities of cytochrome P450 2B1 (pentoxyresorufin O-depentylation), 2E1 (aniline p-hydroxylation) and 3A2 (testosterone 6beta-hydroxylation) isozymes and the 3A2 mRNA levels in liver were decreased by deoxycholic acid. Addition of 1% ursodeoxycholic acid to 1% deoxycholic acid also prevented the decrease in these cytochrome P450 proteins, related enzyme activities and mRNA levels in liver. CONCLUSIONS: These results indicate that, in rats with deoxycholic acid-induced liver injury, ursodeoxycholic acid prevents the decrease in hepatic cytochrome P450 isozymes and suggest that ursodeoxycholic acid is useful for the treatment of liver injury in terms of aiding the normalization of the hepatic drug-metabolizing system.
M Tanaka; H Nakura; T Tateishi; M Watanabe; S Nakaya; T Kumai; S Kobayashi
Related Documents :
8654129 - Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and ot...
4031069 - Biosynthesis of bile acids in cerebrotendinous xanthomatosis. relationship of bile acid...
7435569 - Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic ac...
2375249 - Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine.
2104069 - Review article: bile acid therapy.
2590949 - Effect of natural and structurally modified bile acids on cholesterol metabolizing enzy...
17724089 - Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes a...
6494239 - Biliary and renal excretion of paracetamol in man.
3410889 - Reversed-phase ion-interaction chromatography of leukotrienes, lipoxins and related com...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of hepatology     Volume:  31     ISSN:  0168-8278     ISO Abbreviation:  J. Hepatol.     Publication Date:  1999 Aug 
Date Detail:
Created Date:  1999-09-15     Completed Date:  1999-09-15     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  263-70     Citation Subset:  IM    
Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholagogues and Choleretics / pharmacology*,  therapeutic use
Cholestasis / chemically induced,  drug therapy*,  enzymology
Cytochrome P-450 Enzyme System / drug effects,  metabolism*
Deoxycholic Acid / toxicity
Liver / enzymology*,  pathology
RNA, Messenger / drug effects
Rats, Sprague-Dawley
Ursodeoxycholic Acid / pharmacology*,  therapeutic use
Reg. No./Substance:
0/Cholagogues and Choleretics; 0/RNA, Messenger; 128-13-2/Ursodeoxycholic Acid; 83-44-3/Deoxycholic Acid; 9035-51-2/Cytochrome P-450 Enzyme System

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in ...
Next Document:  Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabol...